What is Thermalin?
Thermalin is a biotechnology firm dedicated to transforming the landscape of diabetes care through the development of novel insulin analogs. The company's research portfolio, rooted in the foundational work of Dr. Michael Weiss at Case Western Reserve University, focuses on high-impact solutions such as ultra-rapid-acting insulin, temperature-stable formulations, and glucose-responsive delivery systems. By addressing the limitations of current insulin therapies, Thermalin aims to improve patient outcomes and quality of life. The company operates at the intersection of academic research and commercial application, supported by a robust network of institutional grants and strategic venture partners.
How much funding has Thermalin raised?
Thermalin has raised a total of $14.3M across 6 funding rounds:
Other Financing Round
$2.2M
Series A
$2.9M
Unspecified
$2.5M
Series B
$5.9M
Debt
$350K
Debt
$429K
Other Financing Round (2010): $2.2M with participation from JumpStart
Series A (2011): $2.9M led by JumpStart
Unspecified (2012): $2.5M, investors not publicly disclosed
Series B (2014): $5.9M featuring Undisclosed
Debt (2020): $350K backed by PPP
Debt (2021): $429K with participation from PPP
Key Investors in Thermalin
JumpStart
JumpStart Inc. is a venture development organization providing capital, services and connections to help entrepreneurs grow, researchers commercialize and corporations innovate.
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Thermalin?
With the infusion of $429K, Thermalin is well-positioned to accelerate its preclinical programs and transition toward more advanced clinical milestones. The company's strategic roadmap emphasizes the commercialization of its proprietary insulin designs, including the highly anticipated once-a-week insulin patch. As the firm continues to navigate the complex regulatory and clinical landscape, the focus will remain on scaling its manufacturing capabilities and securing further partnerships to bring these life-altering therapies to market. The ongoing support from both public health institutions and private investors provides the necessary runway to sustain long-term innovation in the competitive diabetes therapeutics market.
See full Thermalin company page
